BiotechTube
Galectin Therapeutics

Galectin Therapeutics

GALTPhase 3
galectintherapeutics.com

Galectin Therapeutics is pioneering therapies targeting galectin-3, a protein implicated in inflammatory, fibrotic, and malignant diseases. Its primary mission is to address the unmet medical need in MASH cirrhosis, the fastest-growing cause of liver transplantation, through its lead drug candidate belapectin. The company is currently advancing its NAVIGATE Phase 3 clinical trial and recently strengthened its financial position with a $10 million credit facility. Galectin's platform also holds potential in oncology by modulating the tumor microenvironment to enhance immunotherapy responses.

Market Cap
$152.2M
Pipeline
12
1 in Phase 3
Patents
—
Publications
—

AI Company Overview

Galectin Therapeutics is pioneering therapies targeting galectin-3, a protein implicated in inflammatory, fibrotic, and malignant diseases. Its primary mission is to address the unmet medical need in MASH cirrhosis, the fastest-growing cause of liver transplantation, through its lead drug candidate belapectin. The company is currently advancing its NAVIGATE Phase 3 clinical trial and recently strengthened its financial position with a $10 million credit facility. Galectin's platform also holds potential in oncology by modulating the tumor microenvironment to enhance immunotherapy responses.

HepatologyOncologyFibrotic Diseases

Technology Platform

Platform for developing carbohydrate-based drugs that inhibit galectin-3, a protein central to inflammatory, fibrotic, and malignant disease pathways.

Pipeline

12
12 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
belapectin + PlaceboPrevention of Esophageal VaricesPhase 2/3
GR-MD-02 + PlaceboNonalcoholic SteatohepatitisPhase 2
GR-MD-02PsoriasisPhase 2
GM-CT-01 plus 5-FluorouracilColorectal CancerPhase 2
GR-MD-02 + PlaceboHypertension, PortalPhase 2

Opportunities

Belapectin has blockbuster potential as a first-in-class therapy for MASH cirrhosis, a severe condition with no approved drugs.
Success could also validate the galectin-3 platform for expansion into other fibrotic diseases and as a combination therapy in oncology, creating multiple long-term growth avenues.

Risk Factors

The company faces binary clinical risk on the outcome of its single pivotal Phase 3 trial.
Regulatory hurdles, future financing needs for commercialization, and intense competition in the broader MASH therapeutic landscape are significant challenges.

Competitive Landscape

Galectin competes in the crowded MASH space but is strategically focused on the high-need cirrhosis subpopulation. Its main competitors are large pharma and biotech firms developing therapies for earlier-stage MASH. Differentiation lies in belapectin's novel galectin-3 mechanism and its specific target patient group.